Meeting
2024 ASCO Genitourinary Cancers Symposium
Outcomes with neoadjuvant chemotherapy in bladder-preserving treatment for MIBC.
Authors
Michael Glover
Stanford University Medical Center, Stanford, CA
Michael Glover , Agnes Ewongwo , Melissa Usoz , Zachary Kornberg , Hilary Bagshaw , Jay Bakul Shah , Sumit Shah , Yushen Qian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 577)
DOI
10.1200/JCO.2024.42.4_suppl.577
Abstract #
577
Poster Bd #
F4
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Pathologic and survival outcomes following radical cystectomy for “progressive” and “de novo” muscle-invasive bladder cancer: A meta-analysis stratified by neoadjuvant chemotherapy status.
First Author: Leilei Xia
Poster
2023 ASCO Annual Meeting
Survival outcomes in patients with muscle-invasive bladder cancer receiving neoadjuvant chemotherapy stratified by number of cycles.
First Author: Anumita Chakraborty
Poster
2023 ASCO Genitourinary Cancers Symposium
Radical radiotherapy for muscle-invasive bladder cancer: A single centre experience.
First Author: Mayumi Forster
Poster
2023 ASCO Genitourinary Cancers Symposium
Neoadjuvant cisplatin-based chemotherapy followed by selective bladder preservation chemoradiotherapy (CRT) in muscle-invasive urothelial carcinoma of bladder (MIBC): A combined retrospective analysis of two prospective studies.
First Author: Joohyun Hong